Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study

Circ Genom Precis Med. 2020 Feb;13(1):e002767. doi: 10.1161/CIRCGEN.119.002767. Epub 2020 Jan 3.

Abstract

Genome-wide polygenic scores (GPSs) integrate information from many common DNA variants into a single measure of inherited susceptibility, and can identify individuals who are at substantially elevated risk of developing important common diseases., For coronary artery disease, about 8% of the population can be identified who are at triple the normal risk based on genetic variation alone. Among these high polygenic score individuals, adherence to a healthy lifestyle or use of statins may offset increased inherited risk.,

Keywords: coronary artery disease; epidemiology; genetics; genome.

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Benzodiazepines / therapeutic use*
  • Cardiovascular Diseases / drug therapy
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / pathology
  • Case-Control Studies
  • Female
  • Genome, Human*
  • Genome-Wide Association Study*
  • Humans
  • Male
  • Multifactorial Inheritance*
  • Pharmacogenomic Testing
  • Risk Factors
  • Scotland / epidemiology

Substances

  • Anticholesteremic Agents
  • Benzodiazepines
  • evacetrapib